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Abstract: In recent years, an increasing number of studies have shown that elevated expression of
cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types
of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell
lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis
and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC
cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is
overexpressed compared to normal tissues due to a copy number gain. In patients with localized
disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting,
this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the
Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1,
where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5
Cancers 2019, 11, 1540; doi:10.3390/cancers11101540 www.mdpi.com/journal/cancers
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is involved in CRC and disease progression and that it could serve as a prognostic and predictive
biomarker in this disease.
Keywords: colorectal cancer; cyclin-dependent kinase 5 (Cdk5); prognostic and predictive biomarker;
oxaliplatin
1. Introduction
Cyclin dependent kinase (Cdk5) belongs to the cyclin-dependent kinase family of serine/threonine
kinases whose activity depends on a regulatory subunit named cyclin. However, Cdk5 is considered an
atypical Cdk because it binds to non-cyclin proteins p35 (CDK5R1) and p39 (CDK5R2), phosphorylation
in the T-loop is not required for its activation and most of its substrates are not involved in cell cycle
control. The function of this kinase was thought to be restricted to the central nervous system, where it
is indispensable for normal brain development during embryogenesis and controls neuronal migration
or axonal guidance, among others. Deregulation of Cdk5 is widely described in neurodegenerative
diseases such as Alzheimer’s, Parkinson’s, and Huntington’s [1]. In recent years, several studies have
demonstrated that Cdk5 also plays relevant physiological and pathological roles outside of the nervous
system, including transcriptional regulation (through regulation of transcription factors such as p53 or
signal transducer and activator of transcription 3 (STAT3)), cell migration, adhesion, angiogenesis,
and apoptosis [2]. Given that some of these functions are deregulated in tumors and that a great
similarity exists between the cellular and molecular mechanisms orchestrating neuronal migration
during the development of the nervous system and cancer cell migration during metastasis, it is not
surprising that Cdk5 plays a role in cancer.
Cdk5 phosphorylates the STAT3 transcription factor on its Ser-727 residue, leading to increased
proliferation and promotion of tumor formation in medullar thyroid carcinoma and in prostate cancer
cells through the activation of androgen receptor [3,4] or resistance to DNA-damaging agents through
the increased transcription of the DNA-repair gene essential meiotic structure-specific endonuclease 1
(EME1) in colorectal cancer (CRC) cell lines [5]. Cdk5 is involved in the regulation of DNA-damage repair
through the phosphorylation of ataxia telangiectasia mutated (ATM) [6]. Elevated expression has been
described in human pancreatic [7], lung [8], prostate [9], and breast [10] tumors and has been associated
with a worse prognosis. The role of Cdk5 in the proliferation of tumor cells is not clear, but many
studies have demonstrated its implication in cancer migration, invasion, and anchorage-independent
growth. For instance, in pancreatic cancer, two studies showed that Cdk5 inhibition affected tumor
malignant progression in vitro and in vivo. The rat sarcoma (RAS) pathway was reported to have an
important effect on the Cdk5-mediated tumor progression on the one hand because mutant Kirsten
rat sarcoma (KRAS) increased its kinase activity [7] and on the other hand, by participating in its
downstream signaling through phosphorylation of Ras-related (Ral) A and B proteins [11]. In prostate
and melanoma cancer models, the inhibition of Cdk5 resulted in decreased cell motility and metastatic
potential [9,12] and in breast cancer, Cdk5 controlled cancer cell migration and tumor formation by
regulating the phosphorylation of focal adhesion kinase (FAK) at Ser-732, as a downstream step of
transforming growth factor Beta (TGF-B1) signaling, and was shown to be essential for epithelial to
mesenchymal transition (EMT) and cell motility [10]. In CRC, Cdk5 functions as a tumor promoter via
modulating the extracellular receptor kinase 5 (ERK5)—activator protein 1 (AP-1) axis [13] and it has
been associated with oxaliplatin resistance acquisition [14].
To date, little is known about the possible role of Cdk5 as a cancer biomarker. In the present study,
we studied the role of Cdk5 in several CRC cell lines, reproducing results from Zhuang et al. [13] and
most importantly, we investigated the expression patterns of Cdk5 at different molecular levels in a
significant number of human tumor samples from patients at different disease stages with the aim of
evaluating its role as a prognostic and predictive marker in this malignancy.
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2. Results
2.1. Cdk5 and p35 Are Broadly Expressed in CRC Cell Lines
We studied protein levels of Cdk5 and p35 by western blotting in a panel of 10 human CRC cell lines
and detected both at high levels in all cell lines tested (Figure 1A). In contrast, we did not detect the p35
calpain-cleaved product p25, which is recognized by the same antibody. It has been reported that Cdk5
activity is regulated through phosphorylation of Y15 [1], and this phosphorylation is commonly used
as a measure of activity [5,15]. However, based on our experience, this is not a good approach because
Y15 is a highly conserved residue in the Cdk family [16] and the epitope against which these antibodies
are designed is highly homologous for Cdk1, Cdk2, and Cdk5, which could lead to misleading results.
As Cdk5 kinase activity is strictly dependent on the binding with p35/p25, this interaction also serves
as a measure of activity. To study this binding, Cdk5 was immunoprecipitated and p25 was found to
co-immunoprecipitate with Cdk5 in HT29, LoVo, HCT116, and DiFi cell lines (Figure 1B). It was also
found that p25 is more stable than p35 and leads to prolonged kinase activity of Cdk5 [17], suggesting a
Cdk5 hyperactivation in these cell lines.
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Figure 1. Cyclin dependent kinase 5 (Cdk5) and p35 (CDK5R1) expression in colorectal cancer (CRC) 
cell lines. (A) Western blot analysis of Cdk5 and p35 basal expression in a panel of 10 CRC cell lines. 
Alpha-tubulin was used as endogenous control. (B) Representative western blot images showing the 
co-immunoprecipitation of Cdk5 and p35/p25 in the indicated cell lines. Co-immunoprecipitation 
with an immunoglobin G (IgG) antibody was used as a negative control. The results were obtained 
from at least three independent experiments. 
2.2. Cdk5 siRNA-Mediated Gene Silencing Impaired CRC Cells Migration and Invasion 
We investigated how the transient silencing of Cdk5 affected three important characteristics of 
tumor cells: proliferation, migration and invasion. Forty-eight hours after siRNA gene silencing, 
Cdk5 knockdown (siCdk5) efficiency was between 90% and 95% at the protein level in HT29, LoVo, 
DiFi, and HCT116 cell lines (Figure S1A). Under these conditions, we did not observe any effect in 
cell proliferation (Figures 2A and S2A).  
However, we found significantly reduced migration and invasion in HT29 and LoVo siCdk5-
transfected cell lines as compared to siRNA non-target control (siNTC) cells. In contrast, silencing of 
Cdk5 did not decrease the migration and invasion ability of DiFi cells (Figure 2B,C). As HT29 and 
Figure 1. Cyclin dependent kinase 5 (Cdk5) and p35 (CDK5R1) expression in colorectal cancer (CRC)
cell lines. (A) Western blot analysis of Cdk5 and p35 basal expression in a panel of 10 CRC cell lines.
Alpha-tubulin was used as endogenous control. (B) Representative western blot images showing the
co-immunoprecipitation of Cdk5 and p35/p25 in the indicated cell lines. Co-immunoprecipitation with
an immunoglobin G (IgG) antibody was used as a negative control. The results were obtained from at
least three independent experiments.
2.2. Cdk5 siRNA-Mediated Gene Silencing Impaired CRC Cells Migration and Invasion
We investigated how the transient silencing of Cdk5 affected three important characteristics of
tumor cells: proliferation, migration and invasio . orty-eight hours after siRNA gen silencing,
Cdk5 knoc d wn (siCdk5) efficiency was betwee and 95% at the protein level in HT29, LoVo,
DiFi, and HCT116 cell lines (Figure S1A). Under these conditions, we did not obser e a effect in cell
proliferation (Figure 2A and Figure S2A).
However, we found significantly reduced migration and invasion in HT29 and LoVo
siCdk5-transfected cell lines as compared to siRNA non-target control (siNTC) cells. In contrast,
silencing of Cdk5 did not decrease the migration and invasion ability of DiFi cells (Figure 2B,C).
As HT29 and LoVo cell lines harbor mutations in genes from the mitogen activated protein kinase
(MAPK) signaling pathway [18] and the DiFi cell line is considered to be wild type [19], we wondered
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whether an altered MAPK downstream signaling could be behind the observed differences. We took
advantage of another KRAS wildtype (WT) cell line that was engineered to express a mutant form of
KRAS (G12D). Cdk5 silencing caused a modest but statistically significant decrease in migration only
in the SW48 KRAS G12D cell line and not in the KRAS WT. No differences in invasion ability after
Cdk5 silencing were observed in either cell lines (Figure 2D,E).
Another important characteristic of cancer cells is their ability to undergo an unlimited number
of divisions. To study the implications of Cdk5 in their long-term clonogenic capability of CRC
cells, we performed colony formation assays in the HT29 and LoVo cell lines (Figure S2A,B).
We observed a decrease in the number of colonies for siCdk5-transfected cells compared to siNTC cells
in both lines, however, these were only statistically significant for the LoVo cells (p-values 0.198 and
0.046, respectively).
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Figure 2. Effect of Cyclin dependent kinase 5 (Cdk5) siRNA-mediated gene silencing on colorectal
cancer (CRC) cells proliferation, migration and invasion. (A) Graphic representation of HT29, LoVo, DiFi,
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and HCT116 time-dependent cell proliferation after Cdk5 gene silencing measured by propidium iodide
(PI). (B,D) Representative Boyden chamber migration and invasion assays images (4×magnification)
and (C,E) bar graphs showing (mean ± SD) relative cell migration and invasion after Cdk5 silencing
in the indicated cell lines. * p-value < 0.05 relative to control cells siRNA non-target control (siNTC).
The results were obtained from at least three independent experiments.
2.3. Cdk5 and p35 Are Overexpressed in CRC Tumor Samples
We next evaluated Cdk5 and p35 expression in human samples. We included four different
cohorts: A, B, D, and F (Table 1). In cohort A, Cdk5 and p35 proteins were clearly overexpressed
as detected by western blot in tumor tissues as compared to the corresponding normal adjacent
tissues (Figure 3A–C). Cdk5 was detected by immunohistochemistry (IHC) in primary colorectal
tumors from cohort D and scored as either negative or positive (weak and strong staining) (Figure 3D).
A total of 75% of the tumors were positive for Cdk5 staining. We also observed significantly
higher Cdk5 mRNA levels in tumor versus normal adjacent colon samples in two different publicly
available data sets (Colonomics, cohort B, Figure 3E The cancer genome atlas (TCGA), cohort F,
Figure 3F). Using TCGA data (cohort F), we analyzed the Cdk5 gene copy number variation (CNV)
(region chr7:151054008–151057848). We observed a statistically significant increase (p = 7.58 × 10−7) in
the Cdk5 copy number in primary tumors as compared to the corresponding adjacent normal colon
tissues (Figure 3G). The CNV of the Cdk5 gene was strongly correlated (r = 0.55, p = 7.16 × 10−7) to
Cdk5 expression levels in tumor tissue (Figure 3H) and also in a panel of 63 CRC cell lines (r = 0.54,
p = 4.6 × 10−6) (Broad Institute Cancer Cell Line Encyclopedia) (Figure 3I).
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Table 1. Overview of cohort used in the study.
Cohort Type of Samples Cdk5Measurement N Sex Age Metastasis Stage Treatment
Origin of
Samples Available at
Molecular
Data Available
Clinical Data
Available
A Frozen tissueTumor/adjacent WB 12
Male 7 (78%)
Female 2 (22%) 72
Liver 8 (89%)
Lung 1 (11%) IV N/A Tumor Biobank N/A - -
B In silico data Micro array 98 Male 72 (57%)Female 28 (43%) 72 (43-87) - II, MSS
Radical
surgery 96
(98%)
Colonomics
project Colonomics.org RAS, CMS, etc DFS, OS
C Frozen tissue qPCR 37 Male 21 (57%)Female 16 (43%) 78 (37-91) - III
Radical
surgery 36
(97%)
Duran and
Reynals Hospital N/A -
DFS (mean
36.3 months)
OS (mean
42 months)
D FFPE – TMA IHC 52 Male 29 (56%)Female 23 (44%) 62 (37-76)
Liver 37 (71%)
Lung 5 (10%)
Others 10 (19%)
IV
5-FU/OXA
(77%)
CAPE/OXA
(23%)
Private collection ISCIII - DFS (mean9.6 months)
E FFPE – TMA IHC 139 Male 78 (69%)Female 35 (31%) 62 (29-75)
Liver 97 (70%)
Lung 46 (33%)
Others 20 (14%)
IV
5-FU/LV/IRI
(47%)
5-FU/IRI
(53%)
Private collection ISCIII -
DFS (mean
9.4 months)
OS (mean
20.3 months)
F In silico data RNA seq 473 Male 259 (54%)Female 225 (46%) 66 (31-90) - I-IV Various TCGA project
https:
//cancergenome.nih.gov
CNV, RAS,
CMS, etc PFI, OS
Abbreviations: 5-FU/LV/IRI: 5-Fluorouracil/leucovorin/irinotecan; 5-FU/IRI: 5-Fluorouracil/irinotecan; 5-FU/OXA: 5-Fluorouracil/oxaliplatin; CAPE/OXA: Capecitabine/oxaliplatin; CMS:
Consensus molecular subtype; CNV: Copy number variation; DFS: Disease-free survival; FFPE-TMA: Formalin-fixed paraffin-embedded tissue microarray; IHC: Immunohistochemistry;
ISCIII: Instituto de Salud Carlos III; MSS: Microsatellite stable; N/A: Not available; OS: Overall survival; PFI: Progression-free interval; qPCR: Quantitative polymerase chain reaction;
TCGA: The cancer genome atlas; RAS: Rat sarcoma oncogene; WB: Western blot.
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representation of Cdk5 and p35 mRNA expression in 98-paired adjacent normal and tumoral tissues 
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Figure 3. Cyclin dependent kinase (Cdk5) and p35 expression in colorectal cancer (CRC) tumor samples.
Western blot (A) and graphic representation (B,C) of Cdk5 and p35 protein expression, respectively,
in tumoral (T) and normal adjacent (N) tissues of 12 stage IV CRC patients (cohort A). Alpha-tubulin
was used as endogenous control. The p-value was according to paired t-test. (D) Representative
immu ohistochemistry images of Cdk5 taini g in CRC tumor tissues. The uppe pa el shows negative
staining and lower panel positive staining. Scale bar: 100 µm. (E) Graphic representation of Cdk5 and
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p35 mRNA expression in 98-paired adjacent normal and tumoral tissues from stage II microsatellite
stable (MSS) CRC patients (cohort B). (F) Graphic representation of Cdk5 mRNA expression in normal
and tumoral tissues of 38 I-IV CRC patients. Data were obtained from The Cancer Genome Atlas
(TCGA) database (cohort F). (G) Graph representing the Cdk5 copy number (CNV) change between
normal and tumoral tissues in 67 stage I–IV CRC patients (cohort F). (H) Correlation between Cdk5 CNV
and Cdk5 gene expression in 429 stage I–IV CRC patients. p-value according to Pearson correlation test
(cohort F). (I) Correlation between Cdk5 CNV and Cdk5 gene expression in 63 CRC cell lines. The p-value
was according to Pearson correlation test. Data from the Broad Institute Cancer Cell Line Encyclopedia.
2.4. High Cdk5 Levels Correlate with Poorer Prognosis in CRC Patients
Taking into account this data, we wondered whether Cdk5 expression could be a good prognostic
and/or predictive biomarker in patients. To study this possibility, we used several cohorts in which the
expression of Cdk5 was determined through different techniques (Table 1). We categorized data into
high and low Cdk5 expression groups as follows: In cohorts using continuous data (cohorts B, C and F),
patients were assigned to low or high groups according to Cdk5 values below or above the median,
respectively; in those using categorical data (cohorts D and E), patients were grouped as low when
IHC staining was negative or weak and as high when it was strong (Figure 3D). The prognostic
value of Cdk5 expression was studied in two highly homogenous cohorts of localized microsatellite
stable (MSS) CRC cancer patients (cohorts B and C, Table 1). Patients from cohorts B and C were
diagnosed with stage II or stage III cancer, respectively, underwent surgery and did not receive any
adjuvant treatment. In both the cohorts, high Cdk5 levels were associated with shorter disease free
survival (DFS) (p = 0.049 95%, confidence interval (CI) 0.98–5.88 for cohort B and p = 0.048, 95% CI
0.97–7.43 for cohort C) (Figure 4A,B), and also with overall survival (OS) in cohort B (p = 0.022, 95%
CI 0.96–6.48), while no differences could be observed in OS in cohort C (Figure S3A,B). To study the
predictive value of Cdk5 expression in the metastatic setting, we used two different, but again, quite
homogenous cohorts of patients. Cohort D consisted of stage IV CRC patients treated with oxaliplatin
and 5-fluorouracil as the first-line treatment, while patients from cohort E were treated with different
schedules combining irinotecan and 5-fluorouracil (Table 1). As shown in Figure 4C,D, high Cdk5
levels were associated with shorter time to progression (TTP) only in the patients that received an
oxaliplatin-based treatment (median 8.095 vs. 18.23 months, p = 0.043, 95% CI 1.01–4.71) (cohort D,
Figure 4C), as no differences could be observed in the patients treated with irinotecan (median 8.95 vs.
8.42 months, p = 0.45, 95% CI 0.59–1.27) (cohort E, Figure 4D). These analyses were adjusted by age and
sex; however, we performed an additional analysis including metastatic location as another co-variable,
which resulted in an increased significance (p = 0.018, hazard ratio (HR) = 2.72, 95% CI 1.19–6.23).
Similarly, when analyzing the response rates (Chi-square), we only found differences according to Cdk5
levels in the oxaliplatin-treated patients (cohort D) as 87% (13 out of 15 patients) of the low Cdk5 group
had complete or partial response, while only 53% (18 out of 34) of the high Cdk5 group responded
(p = 0.029). In view of these interesting results in the metastatic setting, we wanted to analyze whether
Cdk5 was also predictive for adjuvant oxaliplatin-based therapy response. As we do not have our
own cohort with this patient group, we used the TCGA data (cohort F). When splitting this subgroup
(n = 49) based on high or low Cdk5, we could not observe any difference in the progression free interval
(PFI) (p = 0.64, HR CI) nor OS (p = 0.11, HR CI). It is worth mentioning that when analyzing the entire
TCGA cohort (n = 473, stages I to IV, treated and non-treated), no differences could be observed in PFI
and OS (Figure S3C,D), highlighting the importance of choosing appropriate and well-defined cohorts
of patients to conduct these studies.
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patients, grouped depending on negative (n = 18) or positive Cdk5 (n = 34) immunohistochemistry 
(IHC) staining (cohort D). (D) TTP in 139 stage IV irinotecan-treated patients grouped depending 
on negative (n = 73) and positive (n = 66) Cdk5 IHC staining (cohort E). 
As we observed a difference in migration and invasion when we silenced Cdk5 in our in vitro 
studies, we analyzed the link between Cdk5 expression and several gene sets related to EMT in the 
TCGA cohort. EMT is a well described process whereby cells undergo multiple biochemical changes 
that enable them to assume a mesenchymal phenotype, characterized by enhanced migratory 
capacity, invasiveness, and elevated resistance to apoptosis. We found that only for the TGF-β 
signaling within EMT did high Cdk5 levels correlate with higher pathway activation (p = 0.026, Figure 
S4).  
We observed a difference in the effect of Cdk5 silencing in cell lines depending on their KRAS 
mutational status when studying the migration and invasion of the cells. Furthermore, it has been 
reported that Cdk5 is involved in the signaling cascade downstream of the epithelial growth factor 
receptor (EGFR) receptor [7]. Thus, we wanted to know whether there was a difference in the 
prognostic value of Cdk5 according to KRAS mutations. Patients from cohort B were split according 
to KRAS mutational status (WT or mutated) and Cdk5 expression was again categorized as high or 
low. In the KRAS WT group, patients with high or low Cdk5 levels had similar DFS (Figure 5A); 
however, in the group with KRAS, mutated high Cdk5 levels predicted a statistically very significant 
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Figure 4. Kaplan–Meyer analysis of disease free survival (DFS) and time to progression (TTP) depending
on Cyclin dependent kinase (Cdk5) levels. (A) DFS in 98 stage II colorectal cancer (CRC) patients split
by the median of Cdk5 expression (cohort B). (B) DFS in 37 non-treated stage III CRC patients split by
the median of Cdk5 expression (cohort C). (C) TTP in 52 stage IV oxaliplatin-treated patients, grouped
depending on negative (n = 18) or positive Cdk5 (n = 34) immunohistochemistry (IHC) staining (cohort
D). (D) TTP in 139 stage IV irinotecan-treated patients grouped depending on negative (n = 73) and
positive (n = 66) Cdk5 IHC staining (cohort E).
As we observed a difference in migration and invasion when we silenced Cdk5 in our in vitro
studies, we analyzed the link between Cdk5 expression and several gene sets related to EMT in the
TCGA cohort. EMT is a well described process whereby cells undergo multiple biochemical changes
that enable them to assume a mesenchymal phenotype, characterized by enhanced migratory capacity,
invasiveness, and el vated resistance to apoptosis. We f und that only for the TGF-β sign ling within
EMT did high Cdk5 levels correlate with higher pathway activation (p = 0.026, Figure S4).
We observed a difference in the effect of Cdk5 silencing in cell lines depending on their KRAS
mutational status when studying the migration and invasion of the cells. Furthermore, it has been
reported that Cdk5 is involved in the signaling cascade downstream of the epithelial growth factor
receptor (EGFR) receptor [7]. Thus, we wanted to know whether there was a difference in the prognostic
Cancers 2019, 11, 1540 10 of 17
value of Cdk5 according to KRAS mutations. Patients from cohort B were split according to KRAS
mutational status (WT or mutated) and Cdk5 expression was again categorized as high or low. In the
KRAS WT group, patients with high or low Cdk5 levels had similar DFS (Figure 5A); however, in the
group with KRAS, mutated high Cdk5 levels predicted a statistically very significant poorer DFS
compared to the Cdk5 low group (p = 0.004, 95% CI 1.56–36.46) (Figure 5B). We did not see any
differences in OS in this cohort when grouping according to the KRAS mutational status (Figure S3E,F).
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colorectal cancer (CRC) patients with wildtype (WT) KRAS and split by the median of Cdk5 expression.
(B) DFS for 26 stage II CRC patients with mutated KRAS and split by the median of Cdk5 expression
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2.5. Cdk5 Is Associated with Consensus Molecular Subtype 1
CRC has recently been classified into four consensus molecular subtypes (CMS) [20], namely, CMS1
(microsatellite instability immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal)
subtypes. The subtype with the worst survival probability is the CMS4 [20]. Taking advantage of
the fact that this information was available in cohort F, we wanted to explore whether there was an
association between Cdk5 levels and a specific CMS. First, we checked if CMS-associated OS followed
the same trend as reported previously and indeed, this was the case (Figure S5C). CMS1 displayed
the lowest levels of Cdk5 (Figure 6A,B). For each molecular subtype, we then compared the OS
between patients with high or low Cdk5 levels and did not observe any differences (Figure S5A).
When we analyzed the progression-free interval (PFI), an endpoint similar to DFS and TTP used in our
previous analysis which has been shown to be the most reliable endpoint when analyzing data from
the TCGA-colorectal adenocarcinoma (COAD) database [21], we found that high Cdk5 in the CMS1
correlated with poorer outcomes (p = 0.036, 95% CI 1.07–8.10) (Figure 6C), while no differences were
found in the three remaining molecular subtypes (Figure S5B). It is worth mentioning that the majority
of the CMS1 group were non-metastatic patients (55 M0 and 4 M1).
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(CMS). (A) Dunn and Kruskal–Wallis multiple comparison of Cdk5 expression in CMS in 98 stage II
tumors. Note that only six cases were classified as CMS1 as this cohort was restricted to microsatellite
stabile (MSS) cases (B) ANOVA analysis of Cdk5 expression levels in the CMS in the cancer genome
atlas - colorectal adenocarsinoma - rectal adenocarcinoma dataset (TCGA-COAD-READ) including 410
stage I–IV patients. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001. (C) PFI in the TCGA-COAD
CMS1 subgroup including 78 stage I–IV patients; patients were split according to the median of Cdk5
expression (cohort F).
3. Discussion
Cdk5 has emerged as a possible drug target in several tumors, including CRC. Here, we confirm
previous results implicating its role in CRC pathogenesis [13], but importantly, we report its possible
utility as a prognostic biomarker in this malignancy. It is worth mentioning that our study was
performed in a large number of CRC patients’ samples using different techniques to measure Cdk5
levels, and importantly, in selected groups according to tumor stage and clinical approaches. Given the
relevance of the recent molecular classification of CRC into four consensus subtypes, we also explored
the possible ssociation of Cdk5 overexpr ssion with specific CMS. To our knowledg , this is the most
complete study of these characteristics so f r.
Our results indicate that Cdk5 and its activator p35 are broadly expressed in human CRC cell
lines; however, Cdk5 was found to be mainly bound to p25, the truncated form of p35. The binding of
p25 to Cdk5 is indicative of constitutive activation of Cdk5 [17]. In human colorectal adenocarcinomas,
Cdk5 and p35 were also highly expressed, especially when compared to normal adjacent tissue or
to normal colonic mucosa from healthy donors. Our results are in agreement with those reported
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by Zhuang et al. [13] and are possibly explained by the increased copy number of the Cdk5 gene
found in primary tumors as compared to normal adjacent tissues, a fact that was also pointed out by
Robb et al. [22].
Reduced Cdk5 expression was associated with decreased migration and invasion in vitro but
not with cell proliferation. This has been observed previously in cell lines from different tumor
origins [7,9,11–13]. Our cell lines had mutations in KRAS (LoVo) or in rapidly accelerated fibrosarcoma
B (BRAF) (HT29) genes. Indeed, signaling through the MAPKs is one of the main deregulated pathways
in CRC and other authors had reported an interaction between Cdk5 and different effectors of this
pathway. Unfortunately, in the only previous study conducted for Cdk5 in the context of CRC, all the
cell lines tested had a deregulated MAPK pathway [13]. Therefore, we wanted to include cell lines
with proficient MAPK pathways and compare the effects of silencing the Cdk5 gene. We observed
that in this case, Cdk5 downregulation had no effect on migration or invasion of cells, which is in
agreement with previously published data [7]. It was previously shown that, in a context of RAS/BRAF
mutant CRC, Cdk5 could phosphorylate ERK5 and that the effects of abrogation of Cdk5 expression
were due to the inhibition of ERK signaling [13]. However, we think that this is unlikely as CRC cell
lines with KRAS or BRAF mutations seem to preferentially activate the ERK1/2 pathway and when
treated with ERK5 inhibitors, cell proliferation is unaffected [23,24].
We could successfully translate our results into a clinical setting as high levels of Cdk5 were
associated with a higher risk of relapse in early-stage MSS CRC patients that did not receive any
treatment after primary tumor resection, especially in patients with KRAS-mutant tumors. These results
point to the prognostic value of Cdk5, which seems to be related with a more aggressive phenotype as
we and others have reported in cell lines and in vivo models. Thus, those tumors expressing high levels
of Cdk5 could have an enhanced capacity to invade and migrate from primary sites to metastatic sites.
This is in agreement with what has been reported for other kinds of cancer, for example, breast cancer,
where the Cdk5-FAK pathway downstream of TGF-β signaling is necessary for EMT [10]. Indeed,
when we analyzed the connection between several gene sets related to EMT and Cdk5 expression in
the TCGA cohort, we found that only for TGF-β signaling within EMT did high Cdk5 levels correlate
with greater pathway activation.
We want to remark the homogeneity of these two cohorts of localized CRC patients and the
fact that the patients did not receive any treatment, as this underscores the importance of Cdk5 as
a biomarker in a priori good prognostic tumors. Whether treatment should be considered for these
patients has to be explored in further studies.
We also investigated the predictive value of Cdk5 through analysis of the association between tumor
protein expression and the outcome of metastatic CRC patients receiving two standard chemotherapy
regimens: Oxaliplatin plus 5-fluorouracil and irinotecan plus 5-fluorouracil. Several studies have
shown that Cdk5 plays a role in DNA damage repair and resistance, including the one induced by
oxaliplatin and irinotecan [5,14]. However, we only observed a clear association of Cdk5 protein levels
with response or TTP in patients treated with the former: the higher the Cdk5 levels, the worse the
response or TTP. Whether patients with high Cdk5 tumor levels should be treated with irinotecan-based
schedules rather than oxaliplatin-based schedules requires further investigation. Nevertheless, it should
be noted that our results were based on the protein assessment in primary tumors and not in metastases.
For the moment, these results suggest that Cdk5 could be a good target to develop drugs against;
on the one hand, they could be used in an adjuvant setting to prevent disease relapse and on the
other hand, in a metastatic setting in combination with oxaliplatin. Another possibility would be a
combination with poly (ADP-ribose) polymerase (PARP) inhibitors, as it was reported that Cdk5 gene
silencing conferred high sensitivity to this kind of drugs [25]. Unfortunately, although huge efforts
have been made, the development of specific inhibitors is still an outstanding issue.
Finally, we wanted to explore the possible association between Cdk5 and the recently described
CMSs [20] using the TCGA data. We found that in this cohort, CMS1 tumors had the lowest levels of
Cdk5 and a high Cdk5 expression was only associated with worse progression-free interval in this
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subtype. CMS1 is the so-called immune subtype and it is enriched in microsatellite instable (MSI),
hypermutated, and highly lymphocyte-infiltrated tumors, which usually are responsive to immune
checkpoint blockers. Dorand et al. reported a CD4+ T-cell-dependent rejection of Cdk5-deficient
medulloblastoma cells in mice and an inverse correlation between Cdk5 and CD3+ T-cell infiltration in
human medulloblastoma samples [26]. Experimentally, they showed that IFN-γ-induced programmed
death ligand 1 (PD-L1) upregulation on medulloblastoma cells requires Cdk5. Therefore, we can
speculate that in CMS1 tumors, which display high lymphocyte infiltration, high levels of Cdk5 would
favor the expression of PD-L1 avoiding antitumor immunity. Nevertheless, it is important to stress
that this cohort is very heterogeneous, containing both localized or metastatic tumors and a variety of
treatments. Therefore, this hypothesis should be confirmed in further investigations.
4. Material and Methods
4.1. Human CRC Cell Lines
Human tumor-derived colorectal adenocarcinoma cell lines HT29, LoVo, DLD1, LS513, HCT116,
DLD1, Caco2, LS174T, SW1417, SW480, HCT15, and DiFi from the American Type Culture Collection,
along with SW48 parental and KRAS G12D/+ mutated cell lines (Horizon Discovery Ltd, Cambridge
United Kingdom), were used in the present study. Cell lines were grown as a monolayer in RPMI 1640
(DLD1, LS513, HCT116, SW48, SW480, Caco2, and HCT15), DMEM (HT29, LS174T and SW1417) and
Ham’s F-12 (LoVo) media (Thermo Fisher Scientific, Waltham, MA, USA). DMEM and RPMI media were
supplemented with 10% of heat-inactivated fetal calf serum (FCS) (Reactiva, 08004 Barcelona, Spain),
1% penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA, USA), 2 mmol/L L-glutamine
(Sigma-Aldrich, St. Louis, MO, USA), and 10 mmol/L HEPES (Sigma-Aldrich, St. Louis, MO, USA).
The Ham’s medium was supplemented with 20% of heat-inactivated FCS and 1% penicillin/streptomycin
(Thermo Fisher Scientific, Waltham, MA, USA). All cell lines were cultured at 37 ◦C in a humidified
atmosphere of 5% CO2. Cells were periodically tested for Mycoplasma contamination and authenticated
by short tandem repeat profiling with in-house methods.
The molecular status of cell lines used for experiments: HT29: MSS, KRAS WT, and BRAF mut.
V600E; LoVo: MSI, KRAS mut. G13D, and BRAF WT; HCT116: MSI, KRAS mut. G13D, and BRAF WT;
DiFi: MSS, KRAS WT, and BRAF WT; SW48: MSI, KRAS WT, and BRAF WT.
4.2. Gene Silencing
Cdk5 was transiently silenced using a mix of three different siRNAs (s2825, s2826, and s2827;
(Thermo Fisher Scientific, Waltham, MA, USA) and lipofectamine RNAiMAX in OptiMem medium
according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA). A negative
transcription control (siNTC) (Cat No. AM4611; Thermo Fisher Scientific, Waltham, MA, USA) was
used in all the experiments. Silencing was validated by western blotting and experiments with a
minimum of 70% silencing levels were considered.
4.3. Cell Proliferation
Cell proliferation was analyzed 24, 48, 72, and 96 hours after siRNA Cdk5 silencing. Cells were
permeabilized with 0.3% Triton X-100 and 30 µM propidium iodide (Sigma-Aldrich, St. Louis, MO,
USA) was added and the fluorescence signal corresponding to the cell quantity was measured at
645 nm on the Varioskan reader (Thermo Fisher Scientific, Waltham, MA, USA).
4.4. Colony Formation Assay
HT29 and LoVo siNTC and siCdk5 cells were plated in six-well plates at a density of 300 cells/well.
After 12 days in culture, the cells were washed with phosphate-buffered saline (PBS), fixed with a
methanol/acetic acid (3:1) solution for 10 min and stained with a solution of crystal violet (0.5%) for
10 min. Colonies were counted manually.
Cancers 2019, 11, 1540 14 of 17
4.5. Migration and Invasion
Migration and invasion assays were performed using transwell plates (HTS
Transwell®Sigma-Aldrich, St. Louis, MO, USA). For the invasion assay, the upper chambers were
coated with 21 µL of Geltrex™ (Thermo Fisher Scientific, Waltham, MA, USA). For both the assays,
the lower chambers were filled with a medium containing 10% FCS and cells were seeded in 2%
FCS medium in the upper chamber. Migrated/invasive cells that had reached the lower side of
the membrane were fixed with 4% paraformaldehyde (PFA) and stained with 0.5% crystal violet.
The ImageJ software was used for quantification.
4.6. Immunoprecipitation
Cells were homogenized in lysis buffer and the supernatant was incubated with a Cdk5 primary
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA; (J3): sc-6247) overnight at 4 ◦C. The mix
was incubated 2 hours with protein G-coupled beads (Millipore, St. Louis, MO, USA) and the beads
were washed and boiled for 5 minutes in a loading buffer to detach the protein complex. The protein
levels were examined by western blotting.
4.7. Western Blotting
Cells were homogenized in a radioimmunoprecipitation assay (RIPA) plus buffer. Frozen tissue
samples were disintegrated manually and were homogenized with RIPA plus buffer using the
gentleMACS Dissociator system (Milteny Biotech, Bergisch Gladbach, Germany). Protein concentration
was determined using the DC™ Protein Assay (Bio-Rad Laboratories, Inc., Richmond, CA, USA)
and 50 µg of the protein was loaded and subjected to electrophoresis in 10% Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels (Thermo Fisher Scientific, Waltham, MA,
USA) and transferred onto Polyvinylidene fluoride or polyvinylidene difluoride (PVDF) membranes
(Bio-Rad Laboratories, Inc., Richmond, CA, USA). After blocking (LICOR Biosciences, Lincoln, NE,
USA), membranes were incubated overnight with specific primary antibodies against Cdk5 (Cell
Signaling, Danvers, MA, USA, #2506, 1:1000), p35 (Cell Signaling, Danvers, MA, USA, #2680, 1:300),
and α-Tubulin (Sigma-Aldrich, St. Louis, MO, USA, #T6074, 1:20,000). Membranes were incubated
with IRDye rabbit and mouse secondary antibodies (1:10,000) (LICOR Biosciences, Lincoln, NE, USA)
and scanned and analyzed on the Odyssey imaging system (LICOR Biosciences). Non-cropped western
blots from Figure 1B, Figure 3A, and Figure S1 can be seen in Figure S6.
4.8. Patients’ Samples
Six different cohorts (named A to F), with a total of 811 samples from different patients, were used
in this study. Table 1 shows the characteristics of each cohort. Samples from cohort C were collected at
the Duran i Reynals Hospital. Samples from cohorts D and E belong to a private collection (ISCIII
registered number C.0001505). All the samples were collected according to standard local protocols and
after obtaining informed consent. The Clinical Research Ethical Committee from Hospital Germans
Trias i Pujol provided approval for the study (BB14002; date: 7th March 2014).
4.9. Tissue Microarray and Immunohistochemistry (IHC) Staining
A tissue microarray (TMA) was built for cohorts D and E as previously described [27].
Subsequent immunohistochemistry procedures were applied as reported [27,28], and specific Cdk5
antibodies were used (Abcam, Cambridge, MA, USA, ab40773, 1:200 and Cell Signaling, Danvers, MA,
USA, 2506, 1:200 for validation). Cells with siNTC or siCdk5 gene silencing were used to evaluate
antibody specificity.
Cancers 2019, 11, 1540 15 of 17
4.10. qPCR
CDK5 gene expression was studied by qPCR in cohort C as previously described [14,28]. Briefly,
retrotranscription was performed with moloney murine leukemia virus (MMLV) reverse transcriptase
(Thermo Fisher Scientific, Waltham, MA, USA) and the Cdk5 assay no. Hs00762869_s1 was used
(Thermo Fisher Scientific, Waltham, MA, USA). Relative gene expression quantification was calculated
according to the comparative Ct method as described elsewhere using β-Actin (Thermo Fisher Scientific,
Waltham, MA, USA) as the endogenous control.
4.11. In Silico Data
Two publicly available cohorts were used: Colonomics (NCBI BioProject PRJNA188510) and
TCGA. The colonomics cohort (cohort B) consisted of 98 paired adjacent-normal and tumor tissues
from stage II microsatellite stable patients and 50 colon mucosae samples from healthy donors (246
samples in total). Gene expression data, assessed by Affymetrix Human Genome U219 expression
array, had previously been analyzed [29].
For studies using the TCGA cohort (cohort F), we included all samples annotated as TCGA-colon
adenocarcinoma (COAD) (n = 448) and 25 samples annotated as stage IV TCGA-rectum adenocarcinoma
(READ), 473 samples in total. The classification of TCGA samples into four CMS was in agreement
with Guinney et al. [20]. Different survival event data were retrieved according to Liu et al. [21].
4.12. Statistical Analysis
The data coming from in vitro experiments are presented as mean± standard error of the mean
(SEM) of at least three independent experiments and statistical analysis was performed with Graphpad
Prism V.4 software (San Diego, CA, USA). Comparisons among different experimental conditions were
carried out through the T-student or two-way ANOVA test followed by Bonferroni post-test. Values of
p≤ 0.05 were considered significant.
A survival analysis was performed with the survival and survminer R packages. Kaplan–Meier
curves depicting disease-free survival (DFS), time to progression (TTP), progression-free interval
(PFI), and overall survival (OS) were accompanied with the log-rank test to verify significance in
survival curve differences. The Cox regression hazards models were performed to quantify the effect
of gene expression and survival (adjusted for age and stage). Differences in response to treatment were
evaluated in cohorts D and E by contingency tables and chi-square or Fisher’s exact tests as appropriate.
Regarding TCGA data, comparison between primary and normal tumor samples (gene expression
and copy number alteration segment mean) were performed using paired samples T-tests. Both variables
were compared using the Pearson correlation test. Cdk5 gene expression comparison between different
CMS subtypes was performed using one-way ANOVA.
The GSVA R-package (gene set variation analysis, PMC3618321) was used to compare the gene
expression levels of EMT and TGF-β signaling in EMT pathways in Cdk5 low vs. Cdk5 high tumors.
A Wilcox’s test was performed to evaluate the statistical significance.
5. Conclusions
We combined in vitro studies with the analysis of a high number of tumor samples from different
CRC stages and confirmed that Cdk5 is involved in CRC progression and that it could serve as a
prognostic and predictive biomarker in this disease. Our findings also suggest that Cdk5 could help
decide which patients should receive adjuvant therapy and whether oxaliplatin or irinotecan should
be used in the treatment of metastatic disease.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/10/1540/s1,
Figure S1: Cdk5 siRNA-mediated gene silencing in CRC cells, Figure S2: Effect of Cdk5 siRNA-mediated gene
silencing on HCT116 cell proliferation and HT29 and LoVo colony formation, Figure S3: Kaplan–Meier analysis
of OS and PFI depending on Cdk5 expression and KRAS mutational status, Figure S4: EMT-related enriched
hallmark correlations with Cdk5 expression, Figure S5: Kaplan–Meier analysis of OS and PFI depending on Cdk5
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expression and CMS group, Figure S6: Images displaying non-cropped western blots from Figure 1B, Figure 3A,
and Figure S1.
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